A PHASE I/II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CANNABIDIOL AS A TREATMENT FOR ALCOHOL USE DISORDER COMORBID WITH POSTTRAUMATIC STRESS DISORDER

Brief description of study

The purpose of this research study is to see how safe and effective cannabidiol (CBD) is for the treatment of alcohol dependence comorbid with Post-traumatic Stress Disorder (PTSD). We also would like to assess its effects on thinking, behavior and habits of people with Alcohol Use disorder and PTSD. CBD is a naturally occurring, non-psychoactive compound that is found in the marijuana plant. The United States Food and Drug Administration (FDA) have not approved CBD as a safe or effective treatment for any health condition. Therefore, the use of CBD to treat any disorder is considered experimental. Even though CBD is found in the marijuana plant, it does not make people feel “high” the same way that marijuana does.

Our study teams will respond to the messages between normal office hours of 9AM to 5PM Monday through Fridays, excluding holidays. If this is a medical or psychiatric emergency, please dial 911 or walk to the nearest emergency room.


Clinical Study Identifier: s17-00949
ClinicalTrials.gov Identifier: NCT03248167
Principal Investigator: Charles R. Marmar.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.